These observations suggest that a classical anti-tumor immune response may underlie the regression of CCH, which is mainly based on CD8+ lymphocyte-mediated anti-tumor effects (van der Leun, Thommen & Schumacher, 2020). Here, CD8A is linked to columnar cell hyperplasia of the breast.